**Corrected Table S2:**

**Table S2.** The effect of ABCB1 TTT haplotype in suicides of citalopram users.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **All suicides** | | **All suicides with citalopram or escitalopram prescription** | |
| **Variable and reference category** | **P value** | **OR (95 % CI)** | **P value** | **OR (95 % CI)** |
| *ABCB1,* CGC/CGC or CGC/XXX |  |  |  |  |
| CGC/TTT | 0.928 | 1.02 (0.67–1.55) | 0.961 | 0.99 (0.64–1.54) |
| TTT/TTT, TTT/XXX | 0.397 | 1.19 (0.80–1.77) | 0.476 | 1.16 (0.77–1.76) |
| Other | 0.687 | 0.87 (0.43–1.75) | 0.911 | 0.96 (0.47–1.97) |

**Corrected Table S3:**

**Table S3.** The effect of ABCB1 TTT haplotype in suicides of male citalopram users.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Males** | | **Males with citalopram or escitalopram prescription** | |
| **Variable and reference category** | **P value** | **OR (95 % CI)** | **P value** | **OR (95 % CI)** |
| *ABCB1,* CGC/CGC or CGC/XXX |  |  |  |  |
| CGC/TTT | 0.930 | 0.97 (0.55–1.74) | 0.691 | 0.89 (0.48–1.62) |
| TTT/TTT, TTT/XXX | 0.232 | 0.72 (0.42–1.23) | 0.200 | 0.69 (0.40–1.21) |
| Other | 0.301 | 0.60 (0.23–1.59) | 0.343 | 0.61 (0.22–1.68) |

**Corrected Table S4:**

**Table S4.** The effect of ABCB1 TTT haplotype in violent suicides of female citalopram users.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Violent suicides (females)** | | **Violent suicides (females) with citalopram or escitalopram prescription** | |
| **Variable and reference category** | **P value** | **OR (95 % CI)** | **P value** | **OR (95 % CI)** |
| *ABCB1,* CGC/CGC or CGC/XXX |  |  |  |  |
| CGC/TTT | 0.869 | 0.93 (0.38–2.25) | 0.842 | 1.10 (0.44–2.74) | |
| TTT/TTT, TTT/XXX | 0.205 | 1.71 (0.74–3.95) | 0.229 | 1.72 (0.71–4.17) | |
| Other | 0.875 | 1.13 (0.26–4.88) | 0.707 | 1.33 (0.30–5.88) | |

**Corrected Table S5:**

**Table S5.** The effect of ABCB1 TTT haplotype in non-violent suicides of male citalopram users.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **Non-violent suicides (males)** | | **Non-violent suicides (males) with citalopram or escitalopram prescription** | | |
| **Variable and reference category** | **P value** | **OR (95 % CI)** | **P value** | **OR (95 % CI)** | |
| *ABCB1,* CGC/CGC or CGC/XXX |  |  |  |  | |
| CGC/TTT | 0.269 | 0.68 (0.34–1.35) | 0.181 | 0.60 (0.29–1.27) |
| TTT/TTT, TTT/XXX | 0.133 | 0.62 (0.33–1.16) | 0.140 | 0.61 (0.32–1.18) |
| Other | 0.183 | 0.43 (0.13–1.49) | 0.170 | 0.38 (0.10–1.51) |

**Corrected Table S6:**

**Table S6**. The effect of ABCB1 TTT haplotype in violent suicides of male citalopram users.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Violent suicides (males)** | | **Violent suicides (males) with citalopram or escitalopram prescription** | |
| **Variable and reference category** | **P value** | **OR (95 % CI)** | **P value** | **OR (95 % CI)** |
| *ABCB1,* CGC/CGC or CGC/XXX |  |  |  |  |
| CGC/TTT | 0.307 | 1.45 (0.71–2.95) | 0.481 | 1.31 (0.62–2.75) |
| TTT/TTT, TTT/XXX | 0.714 | 0.88 (0.44–1.75) | 0.588 | 0.82 (0.40–1.68) |
| Other | 0.809 | 0.86 (0.26–2.83) | 0.946 | 0.96 (0.29–3.18) |